Newsroom

Essenlix Corporation, a premier developer, manufacturer, and provider of mobile instant health test solutions for both personal and clinical use using disruptive and proprietary advanced technology, today announced that Essenlix, in partnership with Roche Norway, has won Norway Østfold Hospital System's "Patient At-Home Test" Innovation Partnership that will use Essenlix's iMOST™ as the test platform. Learn More>>

Essenlix and Roche Diagnostics Norway collaborate to deploy the iMOST platform to increase patient at-home testing. Learn More>>

Essenlix Corporation, a premier developer, manufacturer, and provider of mobile instant health test solutions for personal, point-of-care, and clinical use using disruptive and proprietary advanced technologies, today announced that it is partnering with Roche Diagnostics Norway to implement Essenlix’s iMOSTTM platform for the Patient At-Home Test market.

Mobile healthcare startup Essenlix announced on Thursday that it is partnering with Roche Diagnostics Norway on an initiative to increase at-home testing. Learn More>>

iMOST, home self-test artifact! Roche took the lead again! Learn More>>

With the potential to do various tests of different biomarkers in different body fluids with different biochemistries, the first application of iMOST will be iMOST-CBC. CBC or complete blood count is a vital sign of a person’s health, and one of the most common but important lab tests.

The story might sound familiar: An entrepreneur out of a prestigious US university has developed a new blood-testing technology that can be run using only a small sample of blood. Learn More>>